Abstract:Klebsiella pneumoniae (K. pneumoniae) is one of the most common pathogens in hospital-acquired infections. It is often resistant to multiple antibiotics (including carbapenems), and can cause severe pneumonia. In search of effective antimicrobials, we recently developed polyionenes that were demonstrated to be potent against a broad-spectrum of microbes in vitro. In this study, polyionenes containing rigid amide bonds were synthesized to treat multidrug-resistant (MDR) K. pneumoniae lung infection. The polyionene exhibited broad-spectrum activity against clinically-isolated MDR bacteria with low minimum inhibitory concentrations (MICs). It also demonstrated stronger antimicrobial activity against 20 clinical strains of K. pneumoniae and more rapid killing kinetics than imipenem and other commonly used antibiotics. Multiple treatments with imipenem and gentamycin led to drug resistance in K. pneumoniae, while repeated use of the polymer did not cause resistance development due to its membrane-disruption antimicrobial mechanism. Additionally, the polymer showed potent anti-biofilm activity. In a MDR K. pneumoniae lung infection mouse model, the polymer demonstrated lower effective dose than imipenem with negligible systemic toxicity. The polymer treatment significantly alleviated lung injury, markedly reduced K. pneumoniae counts in the blood and major organs, and decreased mortality. Given its potent in vivo antimicrobial activity, negligible toxicity and ability of mitigating resistance development, the polyionene may be used to treat MDR K. pneumoniae lung infection. Statement of Significance Klebsiella pneumoniae (K. pneumoniae) is one of the most common pathogens in hospital-acquired infections, is often resistant to multiple antibiotics including carbapenems and can cause severe pneumonia. In this study, we report synthesis of antimicrobial polymers (polyionenes) and their use as antimicrobial agents for treatment of K. pneumoniae-caused pneumonia. The polymers have broad spectrum antibacterial activity against clinically isolated MDR bacteria, and eliminate MDR K. pneumoniae more effectively and rapidly than clinically used antibiotics. The polymer treatment also provides higher survival rate and faster bacterial removal from the major organs and the blood than the antibiotics. Repeated use of the polymer does not lead to resistance development. More importantly, at the therapeutic dose, the polymer treatment does not cause acute toxicity. Given its in vivo efficacy and negligible toxicity, the polymer is a promising candidate for the treatment of MDR K. pneumoniae-caused pneumonia. (C) 2018 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.

Activity of Imipenem Against Klebsiella Pneumoniae Biofilms in Vitro and in Vivo

Combating biofilm-associated Klebsiella pneumoniae infections using a bovine microbial enzyme

Epidemiology and Resistance Mechanisms to Imipenem in Klebsiella Pneumoniae: A Multicenter Study

Ultrasound-Activatable Phase-Shift Nanoparticle As a Targeting Antibacterial Agent for Efficient Eradication Ofpseudomonas Aeruginosabiofilms

Antioxidant and antifungal activities of extracts from 15 selected hardwood species of Malaysian timber

Activity of Synthetic Peptide KP and Its Derivatives against Biofilm-Producing Escherichia coli Strains Resistant to Cephalosporins

Activity of polymyxin B combined with cefepime-avibactam against the biofilms of polymyxin B-resistant Pseudomonas aeruginosa and Klebsiella pneumoniae in in vitro and in vivo models

Pharmacodynamic modeling of colistin and imipenem against in vitro Pseudomonas aeruginosa biofilms

Klebsiella pneumoniae Biofilms and Their Role in Disease Pathogenesis

A Novel Chemosynthetic Peptide with Β-Sheet Motif Efficiently Kills Klebsiella Pneumoniae in a Mouse Model.

Activity of imipenem/relebactam and comparators against KPC-producing Klebsiella pneumoniae and imipenem-resistant Pseudomonas aeruginosa

Promising strategies for future treatment of Klebsiella pneumoniae biofilms.

Antimicrobial Polymers As Therapeutics for Treatment of Multidrug-Resistant Klebsiella Pneumoniae Lung Infection.

The role of silver nanoparticles alone and combined with imipenem on Ccarbapenem-resistant Klebsiella pneumoniae

In vitro antibacterial activity of three agents of carbapenems

In Vitro Activity of "Old" and "New" Antimicrobials against the Klebsiella pneumoniae Complex

First description of antimicrobial resistance in carbapenem-susceptible Klebsiella pneumoniae after imipenem treatment, driven by outer membrane remodeling

In vitro Activity of Cefepime/Avibactam Against Carbapenem Resistant Klebsiella pneumoniae and Integrative Metabolomics-Proteomics Approach for Resistance Mechanism: A Single-Center Study

Relationship between biofilm formation and antibiotic resistance of Klebsiella pneumoniae and updates on antibiofilm therapeutic strategies

Next generation antibiotic combinations to combat pan-drug resistant Klebsiella pneumoniae

In Vitro and in Vivo Activities of a Novel Β-Lactamase Inhibitor Combination Imipenem/xnw4107 Against Recent Clinical Gram-negative Bacilli from China.